

CURRICULUM VITAE

NAMES

Dr. Emile BIENVENU (PhD, MSc, B.Pharm)



CONTACT DETAILS

Cell phone number (+250) 0788 30 97 65
E-mail address ebienvenu3@gmail.com

PERSONAL DATA

Nationality Rwandan
Gender Male
Date of birth 17 September 1965
Place of birth Nyagatare District, Rwanda
Marital status Married

EDUCATION

- December 2013 **Doctorate of Philosophy (PhD)** in Medical Science (Clinical Pharmacology)
University: University of Gothenburg, Sweden
Thesis Title: “**Optimization of HIV therapy in patients co-infected with tuberculosis: a pharmacogenetic and pharmacokinetic study of efavirenz in Rwandan adult patients undergoing HIV and tuberculosis co-treatment**”. Available at: <http://hdl.handle.net/2077/34069>
- November 2001 **Master of Science (MSc.)** degree in Pharmaceutical Sciences
University: University of The Western Cape, South Africa.
- June 1993 **Bachelor degree in Pharmacy (B.Pharm)**
University: National University of Rwanda, Rwanda.

Research attachment:

Visiting Fellow position at McGill University Center for Intellectual Property Policy, Montreal, Canada (January – March 2008). Involved in the project: *The alternative modeling of Intellectual Property systems in biotechnology innovation*. URL: http://www.wired.com/images_blogs/business/files/intl-exp-biotech.pdf

CURRENT AFFILIATION

University of Rwanda (UR).

CURRENT POSITIONS AND APPOINTMENTS

- **Director of UR-Center for Innovation and Entrepreneurship.** (December 2016 to present)
- **Senior Lecturer** in the College of Medicine and Health Sciences at **UR.** (2014 to present)
- **Chairperson** of the Board of Directors of **RSB** (Rwanda Standards Board). (2009 - 2014; 2014 to present)

ONGOING RESEARCH GRANT

Dr. Emile BIENVENU is the Country Principal Investigator for a EU/EDCTP-supported project aiming at “**strengthening the national pharmacovigilance** infrastructure and post-marketing surveillance system involving mass drug administration and immunization programs being deployed under public health programs in selected East African Countries” (*Acronym: PROFORMA; Grant agreement: CSA2016S-1618; Lead Coordinator: Karolinska Institute, Sweden; Project start date: March 1, 2018; Duration: 5 years; EDCTP grant amount: EUR 3,000,000; Acronym: <http://proforma.ki.se>*).

ON-GOING PHD SUPERVISION

- Jesper Sundell, University of Gothenburg Department of Pharmacology in Sweden, 2015 – 2020.
- John Nyiligira, University of Rwanda, 2019 – 2023.
- Joseph Kabatende, Karolinska Institute in Sweden, 2018 – 2022.
- Colores Uwamariya, University of Gothenburg Department of Infectious Diseases, Sweden; 2020 – 2024.
- Sciffra Uwamungu, University of Gothenburg Department of Pharmacology, Sweden; 2020 – 2024.

GRADUATED PHDS

- Marie Françoise Mukanyangezi, University of Gothenburg Department of Pharmacology, Sweden; Graduated in December 2018.

SKILLS & EXPERIENCE WITH SCIENCE, TECHNOLOGY AND INNOVATION (STI) DUTIES

- Attended a 3-week training course (2017) on “*Intellectual Property Rights*”, organized by WIPO (World Intellectual Property Organization) in collaboration with Sida (Swedish International Development Cooperation Agency) and PRV (Swedish Patent and Registration Office), Stockholm, Sweden (26 August to 17 September, 2017).
- Collaborative consultancy (2016) with Lund University Centre for Innovation, Research and Competence in the Learning Economy (CIRCLE) in Sweden to elaborate the “*Rwandan STI Ecosystem Framework*”.
- In 2010, initiation of an innovation project “*Innovation and use of research results as an Integral Part of Institutional Development*” at University of Rwanda (UR) in collaboration with the Scandinavian Institute for Competitiveness and Development (SICD) based at Blekinge Institute of Technology (BTH) Technoscience Studies Department.

PRIOR POSITIONS

- | | |
|-------------|---|
| 2011 - 2013 | Division Manager / Medical Procurement Division (formerly CAMERWA) at Rwanda Biomedical Center (RBC) |
| 2002 - 2011 | Lecturer in the Faculty of Medicine Department of Pharmacy at National University of Rwanda (NUR) |
| 2002 - 2008 | Executive Secretary for the University Research Office |
| 1998 - 2001 | Assistant Lecturer in the Faculty of Medicine Department of Pharmacy at NUR |
| 1997 - 1998 | Chief Pharmacist at BIOPHARMA, Kigali |
| 1994 - 1996 | Chief Pharmacist at IFRC (International Federation of Red Cross and Red Crescent Societies)-Rwanda Medical Program |
| 1993 - 1994 | Assistant Lecturer in the Faculty of Science Department of Pharmacy at NUR |

OTHER INFORMATION AND SKILLS

- Served as **Board Member** in the Board of Directors of Rwanda Military Hospital (2012 to 2018)
- External examiner at
 - Muhimbili University of Health and Allied sciences (MUHAS) Department of Clinical Pharmacy and Pharmacology; Dar-es-Salaam/Tanzania. (From 2014 to 2017)
 - University of The Western Cape School of Pharmacy; Cape Town/South Africa. (From 2016 to 2018)
- Serve as reviewer for:
 - Tanzania Commission for Science and Technology (COSTECH) (Cluster proposals review),
 - OMICS Group eBooks,
 - *Pharmacology & Pharmacy* (PP) international Journal manuscripts,
 - *International Journal of Infectious Diseases* (IJID) Journal manuscripts.
- Consultancy with WHO, Kigali Office for the preparation of the First Editions of:
 - Rwandan Standard Treatment Guidelines (2007)
 - National Drug Formulary (2007).
- Expert for Drug and Therapeutic Committees (DTC) systems.

SELECTED SCIENTIFIC/ACADEMIC PUBLICATIONS

1. Abbie Barry, Sten Olsson, Omary Minzi, **Emile Bienvenu**, Eyasu Makonnen, Appolinary Kamuhabwa, Margaret Oluka, Anastasia Guantai, Ulf Bergman, Eugène van Puijenbroek, Parthasarathi Gurumurthy, Eleni Aklillu. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. *Drug Safety* (2020), 1-12. URL: <http://link.springer.com/article/10.1007/s40264-019-00898-z>
2. Mukanyangezi MF, Rugwizangoga B, Manzi O, Rulisa S, Hellstrand K, Tobin G, Martner A, **Bienvenu E** and Giglio D. Persistence rate of cervical human papillomavirus infections and abnormal cytology in Rwanda. *HIV Medicine*, 2019, 20, 485 - 495. URL: <https://www.ncbi.nlm.nih.gov/pubmed/31318136>
3. Jesper Sundell, **Emile Bienvenu**, Sofia Birgersson, Angela Äbelö, Michael Ashton, Kurt-Jürgen Hoffmann. Simultaneous quantification of four first line antitubercular drugs and metabolites in human plasma by hydrophilic interaction chromatography and tandem mass spectrometry *Journal of Chromatography B*, Jan. 2019, Vol. 1105, 129-135, DOI: 10.1016/j.jchromb.2018.10.027. URL: <https://www.sciencedirect.com/science/article/pii/S1570023218309218>
4. Mukanyangezi MF, Manzi O, Tobin G, Rulisa S, **Bienvenu E** and Giglio D. Sexual Risk Behaviour in a Cohort of HIV Negative and HIV Positive Rwandan Women. *Epidemiology and Infection*, 2018 Dec., 3:1-9. doi: 10.1017/S0950268818003023. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30501649>
5. Mukanyangezi MF, Sengpiel V, Manzi O, Tobin G, Rulisa S, **Bienvenu E** and Giglio D. Screening for human papillomavirus, cervical cytological abnormalities and associated risk factors in HIV-positive and HIV-negative women in Rwanda. *HIV Medicine*, 2018, 19, 152 -166. URL: <https://www.ncbi.nlm.nih.gov/pubmed/29210158>
<https://www.linkedin.com/pub/emile-bienvenu/98/568/328>

6. **Bienvenu E**, Ashton M, Äbelö A. Influence of CYP2B6 516G>T and long term HAART on population pharmacokinetics of efavirenz in Rwandan adults on HIV and tuberculosis cotreatment. *Pharmacology & Pharmacy*, 2015, 6, 533-546. URL: <http://www.scirp.org/journal/PP/>
7. **Bienvenu E**, Swart M, Dandara C, Ashton M. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. *Antiviral Research* 2014, 102, 44-53. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24316028>
8. **Bienvenu E**, Swart M, Dandara C, Ekman A, Äbelö A, Wonkam A, Ashton M. Frequencies of Single Nucleotide Polymorphisms in Cytochrome P450 Genes (CYP1A2, 2A6, 2B6, 3A4 and 3A5) in a Rwandan Population: Difference to Other African Populations. *Curr Pharmacogenomics Person Med*. 2013, 11(3): 237 – 246. URL: www.sciencedirect.com/science/article/pii/S0166354213003537
9. **Bienvenu E**, Hoffmann KJ, Ashton M, Kayumba PC. A rapid and selective HPLC-UV method for the quantification of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments. *Biomed. Chromatogr.* 2013; 27(11): 1554–1559. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23780715>
10. Twagirumukiza M, Annemans L, Kips JG, **Bienvenu E**, Van Bortel LM. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines. *Trop Med Int Health*. 2010 Mar;15(3):350-61.
11. Matowe L, Waako P, Adome RO, Kibwage I, Minzi O, **Bienvenu E**. A strategy to improve skills in pharmaceutical supply management in East Africa: the regional technical resource collaboration for pharmaceutical management. *Hum Resour Health*. 2008 Dec 23;6:30.
12. **Bienvenu E**, Twagirumukiza M, Seminega B, Niyungeko F, Bugingo R. Study of the efficacy and the tolerance, and the cost-utility of the combination amodiaquine/sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria in adults at Butare University Hospital. *Le Pharmacien d'Afrique*, N° 185, August/September 2005: 7-18. Abstract available on the website http://www.santetropicale.com/kiosque/pharmacien/som_185.htm
13. Muhizi T, Green I. R, Amabeoku G. J, **Bienvenu, E** (2005). An anticonvulsant diterpene lactone isolated from the leaves of *leonotis leonurus* (l) r. br. *The East and Central African Journal of Pharmaceutical Sciences*, 8 (3).
13. **Bienvenu E.**, Amabeoku G. J, Eagles P. K, Scott G and Springfield E. P. (2002). Anticonvulsant activity of aqueous extract of *Leonotis leonurus*. *Phytomedicine*, 9 (3): 217-223.

BOOK

“Evaluation of the Antiepileptic Activity of *Leonotis leonurus*” (ISBN-10: 3639146352) published with VDM Verlag (2009). URL: <http://www.amazon.com/EVALUATION-OF-THE-ANTIEPILEPTIC-ACTIVITY/dp/3639146352>

COMPUTER LITERACY

- Proficiency in Microsoft Office applications (Word, Excel, Power Point, Access and Outlook).
- Proficiency in using software such as the commonly used statistical software "PASW Statistics" (Predictive Analytics SoftWare; formerly SPSS), EndNote Program, and specific pharmacokinetic data analyses tools (WinNonlin, NONMEM).

LANGUAGE (Reading, Speaking, Writing)

- | | | | |
|-------------------|------------------|-------------------|------------------------|
| ● English: | ● French: | ● Swahili: | ● Kinya-rwanda: |
| Fluent | Fluent | Fair | Native language |

I declare that the information of this CV is accurate and true.

January 12th, 2020.



Dr. Emile BIENVENU